Digital and Molecular Detection of Markers for Disease Risk Prediction, Improvement of Diagnostic Detection Accuracy and Implementation for Preventive Measures of Cancer - A Combined Case-control and Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of this study is to identify new markers to predict the risk of developing cancer, primarily breast cancer. For this purpose, researchers will compare data obtained from cancer patients and healthy individuals. If characteristic differences are identified, e.g. in biomarkers, life style or family history, this may indicate a person's increased risk of developing cancer.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: t
View:

• Biological adult (at least 18 years old) women

• Written informed consent for study participation and processing of personal data

• Own smartphone that can run the BayPass mobile application and willingness to use said smartphone for study purposes

• Additional inclusion criterion for case group:

• Pre-existing or current diagnosis of at least one of the following oncological diseases: breast cancer, lung cancer, colorectal cancer, gynecologic cancer (incl. ovarian cancer, endometrial cancer, cervical cancer, fallopian tube cancer, vaginal cancer and vulvar cancer)

Locations
Other Locations
Germany
DigiOnko Präventionsmobil
RECRUITING
Please Refer To Project Homepage For Details (see Link Below)
Contact Information
Primary
Peter A. Fasching, Prof. Dr. med.
fk-digionko@uk-erlangen.de
+49 9131 85 33572
Backup
Hanna Hübner, PD Dr. rer. nat.
fk-digionko@uk-erlangen.de
Time Frame
Start Date: 2024-09-14
Estimated Completion Date: 2025-12
Participants
Target number of participants: 1250
Treatments
Other: Case group (subjects with known pre-existing or current cancer diagnosis)
The case group will consist of subjects with a known pre-existing or current cancer diagnosis, including breast cancer, lung cancer, colorectal cancer or gynecologic cancer
Other: Control group (healthy subjects)
The control group will consist of healthy subjects with no history of cancer
Sponsors
Leads: University of Erlangen-Nürnberg Medical School

This content was sourced from clinicaltrials.gov